Combined activation of the energy and cellular-defense pathways may explain the potent anti-senescence activity of methylene blue

Redox Biology

Volumn 6, Issue , 2015, Pages 426-435

  Atamna, Hani ^a,b   Atamna, Wafa ^b   Al Eyd, Ghaith ^a   Shanower, Gregory ^b   Dhahbi, Joseph M ^c  

^a California USA   (United States)

^b Geisinger Health Geisinger Commonwealth School of Medicine   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AMPK; Complex IV; Mitochondria; NAD; Oxidants; Senescence; Telomeres

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; CYTOCHROME C OXIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METHYLENE BLUE; MITOCHONDRIAL PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SURF1 PROTEIN; UNCLASSIFIED DRUG; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; ADENYLATE KINASE; AICA RIBONUCLEOTIDE; PPARGC1A PROTEIN, HUMAN; RIBONUCLEOTIDE; TRANSCRIPTION FACTOR;

ARTICLE; CELL AGING; CELL ENERGY; CONTROLLED STUDY; ENERGY METABOLISM; HUMAN; HUMAN CELL; LUNG FIBROBLAST; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TELOMERE; ANALOGS AND DERIVATIVES; CELL CYCLE; CELL LINE; DRUG EFFECTS; GENETICS; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; PHOSPHORYLATION; PRECLINICAL STUDY; PROTEIN PROCESSING; TELOMERE HOMEOSTASIS; TRANSCRIPTION INITIATION;

ADENYLATE KINASE; AMINOIMIDAZOLE CARBOXAMIDE; CELL AGING; CELL CYCLE; CELL LINE; DRUG EVALUATION, PRECLINICAL; ELECTRON TRANSPORT COMPLEX IV; ENERGY METABOLISM; HUMANS; METHYLENE BLUE; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; NAD; OXIDATION-REDUCTION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RIBONUCLEOTIDES; TELOMERE HOMEOSTASIS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84941899665     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2015.09.004     Document Type: Article

References (62)

1. Rodier F., Campisi J. Four faces of cellular senescence. J. Cell Biol. 2011, 192:547-556.
2. Baker D.J., Weaver R.L., van Deursen J.M. p21 both attenuates and drives senescence and aging in BubR1 progeroid mice. Cell Rep. 2013, 3:1164-1174.
3. Tyner S.D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Igelmann H., Lu X., Soron G., Cooper B., Brayton C., Park S.H., Thompson T., Karsenty G., Bradley A., Donehower L.A. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002, 415:45-53.
4. Hinkal G.W., Gatza C.E., Parikh N., Donehower L.A. Altered senescence, apoptosis, and DNA damage response in a mutant p53 model of accelerated aging. Mech. Ageing Dev. 2009, 130:262-271.
5. Geng Y.Q., Guan J.T., Xu X.H., Fu Y.C. Senescence-associated beta-galactosidase activity expression in aging hippocampal neurons. Biochem. Biophys. Res. Commun. 2010, 396:866-869.
6. Kassem M., Marie P.J. Senescence-associated intrinsic mechanisms of osteoblast dysfunctions. Aging cell 2011, 10:191-197.
7. Le Maitre C.L., Freemont A.J., Hoyland J.A. Accelerated cellular senescence in degenerate intervertebral discs: a possible role in the pathogenesis of intervertebral disc degeneration. Arthritis Res. Ther. 2007, 9:R45.
8. Jeyapalan J.C., Ferreira M., Sedivy J.M., Herbig U. Accumulation of senescent cells in mitotic tissue of aging primates. Mech. Ageing Dev. 2007, 128:36-44.
9. Paradis V., Youssef N., Dargere D., Ba N., Bonvoust F., Deschatrette J., Bedossa P. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum. Pathol. 2001, 32:327-332.
10. Erusalimsky J.D., Kurz D.J. Cellular senescence in vivo: its relevance in ageing and cardiovascular disease. Exp. Gerontol. 2005, 40:634-642.
11. Martin J.A., Buckwalter J.A. The role of chondrocyte senescence in the pathogenesis of osteoarthritis and in limiting cartilage repair. J. Bone Joint Surg. Am. 2003, 85-A(Suppl 2):S106-S110.
12. Roberts S., Evans E.H., Kletsas D., Jaffray D.C., Eisenstein S.M. Senescence in human intervertebral discs. Eur. Spine J. 2006, 15(Suppl 3):S312-S316.
13. Haruna Y., Kashihara N., Satoh M., Tomita N., Namikoshi T., Sasaki T., Fujimori T., Xie P., Kanwar Y.S. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc. Natl. Acad. Sci. USA 2007, 104:2331-2336.
14. Halloran P.F., Melk A. Renal senescence, cellular senescence, and their relevance to nephrology and transplantation. Adv. Nephrol. Necker Hosp. 2001, 31:273-283.
15. Melk A., Halloran P.F. Cell senescence and its implications for nephrology. J. Am. Soc. Nephrol. 2001, 12:385-393.
16. Hayflick L. The cell biology of aging. Clin. Geriatr. Med. 1985, 1:15-27.
17. Tchkonia T., Zhu Y., van Deursen J., Campisi J., Kirkland J.L. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J. Clin. Investig. 2013, 123:966-972.
18. Campisi J. Cellular senescence and apoptosis: how cellular responses might influence aging phenotypes. Exp. Gerontol. 2003, 38:5-11.
19. Coppe J.P., Desprez P.Y., Krtolica A., Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 2010, 5:99-118.
20. Wagner G. Towards a life prolonging pill? Small molecules with anti-ageing properties. Curr. Drug Targets 2006, 7:1531-1537.
21. Naylor R.M., Baker D.J., van Deursen J.M. Senescent cells: a novel therapeutic target for aging and age-related diseases. Clin. Pharmacol. Ther. 2013, 93:105-116.
22. Atamna H., Mackey J., Dhahbi J.M. Mitochondrial pharmacology: electron transport chain bypass as strategies to treat mitochondrial dysfunction. BioFactors 2012, 38:158-166.
23. Atamna H., Nguyen A., Schultz C., Boyle K., Newberry J., Kato H., Ames B.N. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J. 2008, 22:703-712.
24. Oz M., Lorke D.E., Petroianu G.A. Methylene blue and Alzheimer's disease. Biochem. Pharmacol. 2009, 78:927-932.
25. Roy Choudhury G., Winters A., Rich R.M., Ryou M.G., Gryczynski Z., Yuan F., Yang S.H., Liu R. Methylene blue protects astrocytes against glucose oxygen deprivation by improving cellular respiration. PLoS One 2015, 10:e0123096.
26. Da-Silva S.S., Sajan I.S., Underwood J.P. Congenital methemoglobinemia: a rare cause of cyanosis in the newborn-a case report. Pediatrics 2003, 112:e158-161.
27. Callaway N.L., Riha P.D., Bruchey A.K., Munshi Z., Gonzalez-Lima F. Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol. Biochem. Behav. 2004, 77:175-181.
28. Stack C., Jainuddin S., Elipenahli C., Gerges M., Starkova N., Starkov A.A., Jove M., Portero-Otin M., Launay N., Pujol A., Kaidery N.A., Thomas B., Tampellini D., Beal M.F., Dumont M. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum. Mol. Genet. 2014, 23:3716-3732.
29. Haluzik M., Nedvidkova J., Skrha J. The influence of NO synthase inhibitor and free oxygen radicals scavenger-methylene blue-on streptozotocin-induced diabetes in rats. Physiol. Res. 1998, 47:337-341.
30. Dierks E.A., Burstyn J.N. The deactivation of soluble guanylyl cyclase by redox-active agents. Arch. Biochem. Biophys. 1998, 351:1-7.
31. Forsyth N.R., Evans A.P., Shay J.W., Wright W.E. Developmental differences in the immortalization of lung fibroblasts by telomerase. Aging cell 2003, 2:235-243.
32. Jenkins N.C., Liu T., Cassidy P., Leachman S.A., Boucher K.M., Goodson A.G., Samadashwily G., Grossman D. The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene 2011, 30:265-274.
33. Parrinello S., Samper E., Krtolica A., Goldstein J., Melov S., Campisi J. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat. Cell Biol. 2003, 5:741-747.
34. Ziegler D.V., Wiley C.D., Velarde M.C. Mitochondrial effectors of cellular senescence: beyond the free radical theory of aging. Aging Cell 2015, 14:1-7.
35. Gomez-Cabrera M.C., Sanchis-Gomar F., Garcia-Valles R., Pareja-Galeano H., Gambini J., Borras C., Vina J. Mitochondria as sources and targets of damage in cellular aging. Clin. Chem. Lab. Med.: CCLM/FESCC 2012, 50:1287-1295.
36. Mileykovskaya E., Dowhan W. Cardiolipin membrane domains in prokaryotes and eukaryotes. Biochim. Biophys. Acta 2009, 1788:2084-2091.
37. Mattiasson G., Friberg H., Hansson M., Elmer E., Wieloch T. Flow cytometric analysis of mitochondria from CA1 and CA3 regions of rat hippocampus reveals differences in permeability transition pore activation. J. Neurochem. 2003, 87:532-544.
38. LeBel C.P., Ischiropoulos H., Bondy S.C. Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol. 1992, 5:227-231.
39. Di Stefano G., Manerba M., Vettraino M. NAD metabolism and functions: a common therapeutic target for neoplastic, metabolic and neurodegenerative diseases. Curr. Top Med. Chem. 2013, 13:2918-2929.
40. Salminen A., Kaarniranta K. AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Res. Rev. 2012, 11:230-241.
41. Sohal R.S.Aging cytochrome oxidase activity, and hydrogen peroxide release by mitochondria. Free Radic. Biol. Med. 1993, 14:583-588.
42. Han D., Williams E., Cadenas E. Mitochondrial respiratory chain-dependent generation of superoxide anion and its release into the intermembrane space. Biochem. J. 2001, 353:411-416.
43. 2 in mitochondria. J. Biol. Chem. 2003, 278:2356-2360.
44. Rice L., Phoenix D.A., Wainwright M., Waring J.J. Effect of increasing methylation on the ability of methylene blue to cause diaphorase-catalysed oxidation of NADH. Biochem. Soc. Trans. 1998, 26:S319.
45. Merker M.P., Bongard R.D., Linehan J.H., Okamoto Y., Vyprachticky D., Brantmeier B.M., Roerig D.L., Dawson C.A. Pulmonary endothelial thiazine uptake: separation of cell surface reduction from intracellular reoxidation. Am. J. Physiol. 1997, 272:L673-680.
46. Canto C., Auwerx J. NAD+ as a signaling molecule modulating metabolism. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:291-298.
47. Fernandez-Marcos P.J., Auwerx J. Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis. Am. J. Clin. Nutr. 2011, 93:884S-890.
48. Suwa M., Nakano H., Kumagai S. Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles. J. Appl. Physiol. 2003, 95:960-968.
49. Winder W.W., Holmes B.F., Rubink D.S., Jensen E.B., Chen M., Holloszy J.O. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J. Appl. Physiol. (1985) 2000, 88:2219-2226.
50. Zhang H., Davies K.J., Forman H.J. Oxidative stress response and Nrf2 signaling in aging. Free Radic. Biol. Med. 2015, in press.
51. Atamna H., Paler-Martinez A., Ames B.N. N-t-butyl hydroxylamine, a hydrolysis product of alpha-phenyl-N-t-butyl nitrone, is more potent in delaying senescence in human lung fibroblasts. J. Biol. Chem. 2000, 275:6741-6748.
52. 2-induced premature senescence in primary human keratinocytes. PLoS ONE 2012, 7:e35092.
53. Wang W., Yang X., Lopez de Silanes I., Carling D., Gorospe M. Increased AMP:ATP ratio and AMP-activated protein kinase activity during cellular senescence linked to reduced HuR function. J. Biol. Chem. 2003, 278:27016-27023.
54. Sung J.Y., Woo C.H., Kang Y.J., Lee K.Y., Choi H.C. AMPK induces vascular smooth muscle cell senescence via LKB1 dependent pathway. Biochem. Biophys. Res. Commun. 2011, 413:143-148.
55. Jiang P., Gan M., Ebrahim A.S., Castanedes-Casey M., Dickson D.W., Yen S.H. Adenosine monophosphate-activated protein kinase overactivation leads to accumulation of alpha-synuclein oligomers and decrease of neurites. Neurobiol. Aging 2013, 34:1504-1515.
56. Park S., Kim da S., Kang S., Shin B.K. Chronic activation of central AMPK attenuates glucose-stimulated insulin secretion and exacerbates hepatic insulin resistance in diabetic rats. Brain Res. Bull. 2014, 108:18-26.
57. Corton J.M., Gillespie J.G., Hawley S.A., Hardie D.G. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?. Eur. J. Biochem./FEBS 1995, 229:558-565.
58. Liu L., Trimarchi J.R., Smith P.J., Keefe D.L. Mitochondrial dysfunction leads to telomere attrition and genomic instability. Aging Cell 2002, 1:40-46.
59. Parihar M.S., Brewer G.J. Mitoenergetic failure in Alzheimer disease. Am. J. Physiol. Cell Physiol. 2007, 292:C8-23.
60. Davidson S.M., Duchen M.R. Endothelial mitochondria: contributing to vascular function and disease. Circ. Res. 2007, 100:1128-1141.
61. Fukae J., Mizuno Y., Hattori N. Mitochondrial dysfunction in Parkinson's disease. Mitochondrion 2007, 7:58-62.
62. Harrison D.E., Strong R., Allison D.B., Ames B.N., Astle C.M., Atamna H., Fernandez E., Flurkey K., Javors M.A., Nadon N.L., Nelson J.F., Pletcher S., Simpkins J.W., Smith D., Wilkinson J.E., Miller R.A. Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging cell 2014, 13:273-282.